Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe bottom revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded a new publication citation for Chen MF et al., Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2025 Oct 23:103505. Removed the earlier print-entry citation (S1556-0864(25)02859-X) in PubMed publications.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.4.2 is displayed instead of v3.4.1, indicating a minor version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check31 days agoChange DetectedThe page footer now displays Revision: v3.4.1, replacing the previous Revision: v3.4.0.SummaryDifference0.1%

- Check38 days agoChange DetectedAdded a glossary display option and new page metadata labels ('Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and updated the site revision to v3.4.0. Removed the older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and the previous revision note v3.3.4.SummaryDifference0.2%

- Check53 days agoChange DetectedA new revision tag v3.3.4 was added and the previous v3.3.3 tag removed; this represents a minor update not affecting the displayed study information.SummaryDifference0.1%

Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.